21 December 2012 | News | By BioSpectrum Bureau
China CyberKnife explores application in prostate and lung tumors
China CyberKnife forum explores applications in treating cancer
Singapore: About 100 attendees from hospitals using CyberKnife Systems in China were brought together at the Second China CyberKnife Forum. The event was co-organized by the Radiation Oncology Committees of Chinese Anti-Cancer Association and Chinese Medical Association.
CyberKnife, which is developed by US-based Accuracy, is designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy.
"The China CyberKnife Forum featured clinical and technical presentations on a broad range of CyberKnife indications including intracranial, lung, liver, prostate and pancreatic tumors. China CyberKnife Forum provides a great platform to discuss the clinical applications and share best practices among users in the country, which we hope will ultimately bring greater benefits to patients," said Professor Pan, director of the CyberKnife and Gamma-knife Center, Shanghai Huashan Hospital Fudan University.
Regional and international speakers invited by Accuray also shared best practices on the use and efficacy of the CyberKnife System in treating prostate and lung tumors in Taiwan and the United States respectively.
"The CyberKnife Forum continues to be invaluable in learning and sharing among our clinicians. The clinical data presented during this year's forum supports the growing usage of full-body radiosurgery in China. It also highlights CyberKnife clinical excellence in providing safe, effective and comfortable care for patients," said Ms Cynthia Chan, senior director of medical affairs, Accuray Asia.